Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma

EVRY, France, February 27 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, announced the results of its first set of data pertaining to Nova21027, its innovative BAK-free latanoprost formulation for glaucoma. Novagali communicated about "Ocular safety compari...

Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)

- Improved Pharmacokinetic Characteristics of Naltrexone SR Associated with Better Tolerability in Clinical Trials - PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity and other ce...

Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients

LAUSANNE, Switzerland, September 25 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announces the filing of an application with the European Agencies for the approval of its n...

Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels

WELLESLEY HILLS, Mass., Aug. 25 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today that all pharmaceutical intellectual property will be sold at a sealed bid auction on October 10, 2008. SR...

Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer

- Presentation of Efficacy and Safety Phase III Results - LAUSANNE, Switzerland, Feb. 12 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, presented today at the ...

Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure

PHILADELPHIA, Jan. 14 /PRNewswire/ -- Kibow Biotech, Inc. is pleased to announce that it has been granted an International Patent Cooperation Treaty (PCT) patent from Australia, China and India. The approved patent, "Prebiotic and Probiotic Compositions and their Method of use for Gut-based Th...

ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting

IRVINE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), presented today results from the Company's two Phase III clinical trials of Xibrom(TM) (bromfenac sodium ophthalmic solution) QD (once- daily) formulation, a new formulation of ISTA's ocular, non-ste...

New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation

- Results Presented at ICAD 2008 Highlight Significant Improvement in Cognitive Performance and Global Clinical Status in Patients with Alzheimer's Disease - CHICAGO, July 30 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) presented today positive P...

NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation

SAN MATEO, Calif., July 11 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced the initiation of its Phase 1 clinical trial (study C203) of NGX-1998. The product candidate i...

ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation

IRVINE, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today reported topline results of a clinical trial of Xibrom(TM) (bromfenac sodium ophthalmic solution) QD (once-daily) 0.18% formulation, a new formulation of ISTA's ocular, non- steroidal ant...

Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR

Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR CAMBRIDGE, Mass. and GAITHERSBURG, Md., April 10, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today announced that data from a preclinica...

SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme

Study Showed Bioequivalence LONDON, UK and ATLANTA, US, May 14, 2007 - SkyePharma PLC (LSE:SKP; NASDAQ:SKYE) and Sciele Pharma. Inc. (NASDAQ:SCRX) today announce the successful completion of the clinical trial programme for the new formulation of Sular, a calcium channel blocking agent for the ...

OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation

Orexigen(TM) is evaluating zonisamide SR as a novel component in EMPATIC(TM) Phase IIb obesity trial SAN DIEGO, June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of central nervous system disorders with an initial focus o...

Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration

PARIS--(BUSINESS WIRE)--Jun 11, 2007 - Regulatory News-Ipsen (Paris:IPN) announced today that the preliminary data from the ongoing phase III study for its investigational 4-month formulation of triptorelin do not support the expected sustainable blood levels of triptorelin for a duration of 4 mont...

Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes

Data Also Support Drug's Efficacy at Improving Glycemic Control and Reducing Diabetic Cardiovascular Complications CHICAGO, Ill., June 23, 2007 /PRNewswire/ -- VeroScience, LLC, in conjunction with its commercialization partner S2 Therapeutics, Inc., reported today the results of its Phase IIIb cl...

Labopharm files New Drug Submission with Health Canada for novel antidepressant

...roducts Directorate of Health Canada for its novel formulation of the antidepressant trazodone. "We are pleased...esents a significant opportunity for our trazodone formulation and we are currently in discussions with potential... disorder demonstrated the efficacy of Labopharm's formulation as a treatment for depression, as well as its posi...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...l, Blood, 25 June 2009; Vol. 113, No. 26, pp. 6533-6540. Positive results from a separate Phase 1-2a study in MDS patients involving an intravenous formulation of TELINTRA were published earlier in the Journal of Hematology and Oncology, 13 May 2009; Vol. 2, No.20, pp. 20-32. The findings reported from thes...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...ped utilizing Elan Drug Technologies' proprietary NanoCrystal((R)) Technology. Using this technology increases the rate of dissolution and enables the formulation of an aqueous suspension for once-monthly intramuscular administration. INVEGA(R) SUSTENNA(TM) is manufactured by Janssen, Division of Ortho-McNeil-J...

Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture

...chnology takes a dual approach to healthy skin by preserving both proteins and lipids during cleansing which is critical for optimal skin health. The formulation is comprised of sodium lauroyl isethionate, a mild cleanser that reduces protein damage, and 100% skin-compatible natural moisturizers, including stea...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

...g User Fee Act (PDUFA) date of August 16, 2009. NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 ...

Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364

...proof-of-concept studies that led to human clinical trials. An intravenous formulation of semapimod was shown to have significant anti-inflammatory activity in Ph...in Crohn's disease, psoriasis and ERCP-induced pancreatitis. However, that formulation caused dose-limiting local reactions, such as phlebitis. To overcome this ...

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

...ential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolytics...

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

...uidosomes(TM)-tobramycin. This drug is a liposomal formulation of tobramycin and an innovative treatment for infe...s(TM)-tobramycin could be a totally new antibiotic formulation that addresses microbiological needs that no other...opment of its lead product, an inhalable liposomal formulation of tobramycin. Axentis Pharma's lead product is de...

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

...(TM) in the U.S. with an option for global rights. Urocidin is a patented formulation of Mycobacterial Cell Wall-DNA Complex (MCC) developed by Bioniche for the ...l trial centres immediately. About Urocidin(TM) Urocidin is a formulation of MCC, a sterile mycobacterial cell wall-DNA complex composition that has ...

New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects

...ses of kinase inhibitors that cause unacceptable toxicity in humans. Proper formulation might circumvent side effects and improve their general therapeutic efficac...matic approach in which chemical modification of NMEs is combined with drug formulation studies. This will lead to a versatile drug delivery platform for future cl...

Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value

...mited treatment options. 3. Transdermal Patch formulation Clinical trials of a once-a-week transdermal patch formulation of donepezil, which include a bioequivalence study compared to the currently marketed formulation of donepezil, are currently being conducted by Tei...

Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237

...ent of chronic obstructive pulmonary disease (COPD). NVA237 is a dry powder formulation for oral inhalation of glycopyrronium bromide, a LAMA with a rapid onset of...develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies...

Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)

...ghteen clinical sites throughout the United States are participating in the study. About ARIKACE(TM) ARIKACE is a sustained-release formulation of the antibiotic amikacin, which encloses the drug in nanocapsules of lipid called liposomes. This advanced pulmonary liposome technology prolongs th...

King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

...ormulation, contain pellets of an extended-release formulation of morphine sulfate surrounding an inner core of n...cohol to interact with drugs and/or disrupt a drug formulation matrix is a prevalent safety concern. For extended... added concern that ethanol (EtOH) may disrupt the formulation mechanism leading to increased bioavailability of ...

Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies

...ies completed, Covance's team of experts deliver integrated AME study services, including on site Authorized Nuclear Pharmacist-formulated doses; cGMP formulation testing; AME study conduct and analysis of parent compound; total radioactivity; pharmacokinetic interpretation; and metabolite profiling and identifi...

When It Comes to Natural Remedies for Hormonal Balance, the Proof Is in the Clinical Research

...ational's Femmenessence , made from the proprietary ingredient Maca-GO (R), www.naturalhi.com , a concentrated organically certified, proprietary formulation of the Peruvian herb maca. Hormones are the body's directors, controlling the activity of cells and organs, affecting much more than just menopau...

ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease

...ctivitis sicca) using a new, proprietary, low-dose formulation of bromfenac, the active ingredient in Xibrom(R) (...rther support our belief that a modified, low-dose formulation of bromfenac has the potential ability to effectiv... of future or ongoing studies with ISTA's low-dose formulation of bromfenac, ISTA's intention to select one or mo...

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans

...rietary liposomal technology we created an inhaled formulation that is free from irritating solvents and optimize....121-129]. About PARI Pharma's Inhaled L-CsA formulation PARI Pharma's L-CsA is a low-dose, inhaled, liposomal cyclosporine A formulation that aims to improve the pharmacological profile, ...

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

...on Drug User Fee Act (PDUFA) date of August 16, 2009. NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 ...

Heart Disease Treatment Breakthrough

...isease were made public for the first time at the British Cardiovascular Society annual conference in London on Monday (1st June). The Ateronon formulation combines lycopene with milk and soy-based proteins to produce a much smaller, and more bio-available molecule. The early studies have shown that Atero...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...nd somatostatin analogs and novel cytotoxics. Sandostatin LAR important safety information Sandostatin LAR is a long-acting, injectable depot formulation of octreotide acetate, that is approved for the treatment of acromegaly, diarrhea/flushing episodes associated with advanced carcinoid tumors and prof...

Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections

...tion, so activity against these organisms is advantageous even without bacterial confirmation. "Physicians also rank availability in intravenous formulation and a low propensity to induce resistance as other important drug attributes that influence their selection in antibiotics," added Ms. Arias. "While s...

Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults

...gency room or hospital setting. These formulations are bioequivalent, meaning doses do not need to be adjusted when converting from IV to oral. The IV formulation of Vimpat(R) does not require dilution prior to administration. Vimpat(R) was approved by the U.S. Food and Drug Administration in October 2008 f...

Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop

...d there can be no assurance that any future studies will demonstrate that subcutaneous infusion of Cinryze is safe or effective or that a subcutaneous formulation of Cinryze will receive regulatory approval. These factors, and other factors, including, but not limited to those described in ViroPharma's annual re...

New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal

...ich affect established pain pathways, are thought to be responsible for pain relief with tapentadol. It is also being developed in an extended release formulation for chronic pain. Study Design This Phase 3, double-blind, randomized, active- and placebo-controlled, parallel group, multi-center trial of...